



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Anti-HLA-DR [1D10 (Hu1D10; Apolizumab)] Standard Size Ab03369-10.0

Isotype and Format: Human IgG1, Kappa

Clone Number: 1D10 (Hu1D10; Apolizumab)

Alternative Name(s) of Target: CD74; HLA class II histocompatibility antigen gamma chain; HLA-DR antigens-associated invariant chain; Ia antigen-associated invariant chain; Ii; p33

UniProt Accession Number of Target Protein: P04233

Published Application(s): IP, therapeutic, FC

Published Species Reactivity: Human

Immunogen: The original mouse antibody 1D10 was generated by immunizing female BALB/c mice intraperitoneally with human large cell lymphoma HO-85. Humanized version of this antibody was generated by grafting CDRs of the parental mouse antibody onto human framework regions.

Specificity: This antibody recognizes a variant epitope on the beta chain of HLA-DR. It can bind some but not all HLA-DR beta chains. The antigen that this antibody binds is expressed on lymphocytes, macrophages, and dendritic (mesenchymal) cells and on most B cell neoplasms. HLA-DR is an MHC class II cell surface receptor encoded by the human leukocyte antigen complex on chromosome 6 region 6p21.31. HLA-DR is also involved in several autoimmune conditions, disease susceptibility and disease resistance. The primary function of HLA-DR is to present peptide antigens, potentially foreign in origin, to the immune system for the purpose of eliciting or suppressing T-(helper)-cell responses that eventually lead to the production of antibodies against the same peptide antigen.

Application Notes: This antibody is the humanized version of anti-HLA-DR mouse parental antibody called 1D10. This antibody is capable of recognizing a majority of B-cell malignancies. This antibody is capable of inducing complement-mediated cytotoxicity, antibody dependent cell cytotoxicity and direct apoptosis of B cells expressing HLA-DR. The original mouse version does not possess these characteristics. This antibody has similar affinity to human HLA-DR as compared to its parental mouse antibody (PMID: 11477560). This antibody was also used for the generation of a bispecific antibody in combination with anti-CD3e antibody M291 (Visilizumab) (US6129914).

Antibody First Published in: Kostelny et al. Humanization and characterization of the anti-HLA-DR antibody 1D10. Int J Cancer. 2001 Aug 15;93(4):556-65. [PMID:11477560](#)

Note on publication: This paper describes the generation and characterization of the humanized version of anti-HLA DR antibody 1D10.

Product Form

Size: 200 µg Purified antibody.

Purification: Protein A affinity purified

Supplied In: PBS with 0.02% Proclin 300.

Storage Recommendation: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Concentration: 1 mg/ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.